Dr. Reddy's ZEMBRACE SymTouch Migraine Injection Commercially Available In U.S

(RTTNews) - Dr. Reddy's Laboratories (500124, DRREDDY, RDY) and its unit Promius Pharma LLC Tuesday announced that ZEMBRACE SymTouch for migraine is now commercially available in the U.S. ZEMBRACE SymTouch (Sumatriptan Injection) is available as a box of 4 autoinjectors.

ZEMBRACE SymTouch is a prefilled, low-dose, ready-to-use, 2-step autoinjector containing 3 mg of sumatriptan, a selective 5-HT1B/ID receptor agonist.

The prescription medicine is used to treat acute migraine headaches with or without aura in adults who have been diagnosed with migraine. The subcutaneous injection may lead to rapid relief of migraine.

Different types of medications can be used to treat different types of migraine attacks.

Roger Cady, MD, Associate Executive Chairman of the National Headache Foundation, said, "ZEMBRACE SymTouch is a welcome addition to the toolkit for acute treatment of migraine. This 3-mg, easy to-use subcutaneous injection of sumatriptan may be desired by many migraine patients who need a medication that can rapidly treat migraine attacks. Also, the 3-mg dose allows for up to 4 doses of ZEMBRACE SymTouch in a 24-hour period, thus allowing dosing flexibility for patients."